Abstract: The present disclosure relates to methods of treating organic acidemias with 2.2-dimethylbutyric acid or pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a disc brake rotor; the rotor including a central hub coaxial with and supporting annular rings which form an inboard brake band and an outboard brake band for engagement with brake pads of a disc brake; the inboard brake band and the outboard brake band maintained in a parallel spaced apart configuration by an array of pillars; the array of pillars arranged in repeating families of individually shaped pillars. Also disclosed is a method of optimising shape of pillars in groups of pillars of a disc brake rotor; the disc brake rotor comprising inner and outer annular brake bands maintained in spaced apart parallel configuration by the groups of pillars; the method including the steps of:—arranging the pillars into repeating families of pillars; each family lying in a 22.

Abstract: The present disclosure provides nucleic acid based therapeutics, such as small interfering ribonucleic acids (siRNAs), which repress expression of human SLC10A1 mRNA transcripts for treating NTCP associated diseases and disorders. Also provided herein are methods of treating cholestatic disorders, HDV, HBV, NAFLD, and NASH with the siRNAs, conjugates and compositions provided herein.

Abstract: The present invention relates to siRNA molecules targeting a SLC10A1 mRNA transcript and methods of using the siRNA compositions for treatment of a NTCP associated disorder.

Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.

Abstract: A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.

Abstract: A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I); pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

Abstract: The present invention provides compounds of formula (I) wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.